A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation
Open accessThe DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusion every 3 weeks, without antiallergic premedication. The starting dose was 10 mg m(-2), and the dose was escalated according to the accelerated titration method. Nineteen patients were recruited. The tumour types treated included pancreatic (n=11), bile duct (n=5), gastric (n=2), and colonic (n=1) cancers. Neutropenia was the most common haematological toxicity. A grade 3 fever developed in one patient given 180 mg m(-2). No other grades 3 or 4 nonhaematological toxicities, including neuropathy, was observed during the entire study period. DLTs occurred in two patients given 180 mg m(-2) (grade 4 neutropenia lasting for more than 5 days). Thus, this dose was designated as the MTD. Grade 2 hypersensitivity reactions developed in only one patient given 180 mg m(-2). A partial response was observed in one patient with pancreatic cancer. The maximum concentration (C(max)) and area under the concentration (AUC) of NK105 were dose dependent. The plasma AUC of NK105 at 150 mg m(-2) was approximately 15-fold higher than that of the conventional PTX formulation. NK105 was well tolerated, and the RD for the phase II study was determined to be 150 mg m(-2) every 3 weeks. The results of this phase I study warrant further clinical evaluation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Some other paclitaxel polymeric micelle formulations, such NK105, were also reported to have lower toxicity in clinical trials compared to Taxol® [238].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a phase I trial of NK105, nineteen patients with various type of cancers (pancreatic, bile duct, gastric, and colonic) were recruited to examine the safety and PK of NK105. NK105 doses ranging from 10 mg/m2 to 180 mg/m2 was administered to patients without premedication. The MTD of NK105 was determined to be 180 mg/m2 due to dose limiting hematological toxicity (neutropenia). The PK profile of”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [238]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · cited 1×
“Tumour response was evaluated according to the Response Evaluation Criteria in Solid Tumors criteria (Therasse et al, 2000).”
MethodMatsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundSelf-citationThe dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269 · cited 2×
“These characteristics, which are unique to solid tumours, constitute the basis of the enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000; Duncan, 2003).”
BackgroundGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 2×
“In this trial, Abraxane demonstrated significantly higher response rates, compared with standard PTX, and a significantly longer time to progression (Gradishar et al, 2005).”
BackgroundRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundHypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174 · cited 1×
“However, the use of Cremophor EL is known to be associated with acute hypersensitivity reactions (Weiss et al, 1990; Rowinsky and Donehower, 1995; Kloover et al, 2004).”
BackgroundTaxol: A Novel Investigational Antimicrotubule Agent
Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,090
Kim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · cited 1×
“These preparations include Xyotax (polyglutamate-conjugated PTX; Singer et al, 2003; Boddy et al, 2005), Abraxane (PTX coated with albumin; Ibrahim et al, 2002; Deisai et al, 2003; Nyman et al, 2005), and Genexol-PM (a PTX micelle in which PTX has been simply solubilised; Kim et al, 2004).”
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Research works printed but not linked: 1
- Deisai N, Trieu V, Yao R (2003) Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol, role of a novel albumin transporter mechanism. 26th Annual San Antonio Breast Cancer Symposium San Antonio, TX
Cited by
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered Release
Oerlemans, C., Bult, W., Bos, M., Storm, G., Nijsen, J. F. W., & Hennink, W. E. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0233-4 · Cited by 947
“NK105 PEG-P(aspartate) Paclitaxel 85 nm Advanced stomach cancer II (6,24)”
BackgroundProgress of drug-loaded polymeric micelles into clinical studies
Cabral, H., & Kataoka, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.042 · Cited by 837
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
Lu, Y., & Park, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.08.042 · Cited by 572
Polymeric micelles drug delivery system in oncology
Gong, J., Chen, M., Zheng, Y., Wang, S., & Wang, Y. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.012 · Cited by 570
Paclitaxel Nano-Delivery Systems: A Comprehensive Review
Ma, P. (2013) · Journal of Nanomedicine & Nanotechnology · doi:10.4172/2157-7439.1000164 · Cited by 559
“In phase I clinical studies, the MTD of NK 105 was determined to be 180 mg/m2 and the plasma AUC was 15-fold higher than Taxol at the dose of 150 mg/m2 [115].”
MethodKim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903380446 · Cited by 549
“In spite of seductive advantages, only four micelle systems have been clinically examined [10-16].”
BackgroundTalelli, M., Barz, M., Rijcken, C. J. F., Kiessling, F., Hennink, W. E., & Lammers, T. (2015) · Nano Today · doi:10.1016/j.nantod.2015.01.005 · Cited by 506
Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles
Matsumura, Y., & Kataoka, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01103.x · Cited by 501
Self-citationPolymeric nanoparticles: the future of nanomedicine
Banik, B. L., Fattahi, P., & Brown, J. L. (2016) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1364 · Cited by 485
Poly (2-oxazoline) s as polymer therapeutics
Luxenhofer, R., Han, Y., Schulz, A., Tong, J., He, Z., Kabanov, A. V., & Jordan, R. (2012) · Macromolecular Rapid Communications · doi:10.1002/marc.201200354 · Cited by 470
Multifunctional polymeric micelles for delivery of drugs and siRNA
Jhaveri, A. M., & Torchilin, V. P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00077 · Cited by 466
“Polymeric micelles, while allowing for the different modifications individually, also offer a platform that allows for integration of multiple components within a single micelle.”
BackgroundPaclitaxel: What has been done and the challenges remain ahead
Bernabeu, E., Cagel, M., Lagomarsino, E., Moretton, M., & Chiappetta, D. A. (2017) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2017.05.016 · Cited by 413
The battle of “nano” paclitaxel
Sofias, A. M., Dunne, M., Storm, G., & Allen, C. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.02.003 · Cited by 401
Caster, J. M., Patel, A. N., Zhang, T., & Wang, A. (2017) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1416 · Cited by 380
Polymeric micelles: nanocarriers for cancer-targeted drug delivery
Zhang, Y., Huang, Y., & Li, S. (2014) · AAPS PharmSciTech · doi:10.1208/s12249-014-0113-z · Cited by 367
“NK105 (16), pluronic polymer-bound doxorubicin (SP1049C) (17) and NK911, a micelle-encapsulated doxorubicin (18).”
Nanoparticle Technologies for Cancer Therapy
Alexis, F., Pridgen, E. M., Langer, R., & Farokhzad, O. C. (2010) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-00477-3_2 · Cited by 364
“2005), NK105 (Hamaguchi et al. 2007), and NK911 (Matsumura et al.”
BackgroundMikhail, A. S., & Allen, C. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.04.010 · Cited by 328
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Lu, H., Wang, J., Song, Z., Yin, L., Zhang, Y., Tang, H., Tu, C., Lin, Y., & Cheng, J. (2014) · Chem. Commun. · doi:10.1039/c3cc46317f · Cited by 300
Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy
Avramović, N., Mandić, B., Savić-Radojević, A., & Simić, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12040298 · Cited by 296
“Vilar et al. reported a similar DOX formulation of an amphiphilic poly(ethylene oxide)-b-poly(aspartic acid)(PEO-b-PAsp) copolymer, in which the hydrophilic polymer PEG was substituted with PEO [57].”
BackgroundInfluentialGlycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain
Anraku, Y., Kuwahara, H., Fukusato, Y., Mizoguchi, A., Ishii, T., Nitta, K., Matsumoto, Y., Toh, K., Miyata, K., Uchida, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00952-3 · Cited by 294
Applications of polymer micelles for imaging and drug delivery
Movassaghian, S., Merkel, O. M., & Torchilin, V. P. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1332 · Cited by 276
Poly (amino acid) micelle nanocarriers in preclinical and clinical studies
Matsumura, Y. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.11.010 · Cited by 275
Self-citationPolymeric micelles in oral chemotherapy
Bromberg, L. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.01.018 · Cited by 264
Improving Drug Potency and Efficacy by Nanocarrier-Mediated Subcellular Targeting
Murakami, M., Cabral, H., Matsumoto, Y., Wu, S., Kano, M. R., Yamori, T., Nishiyama, N., & Kataoka, K. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001385 · Cited by 262
Peynshaert, K., Manshian, B. B., Joris, F., Braeckmans, K., De Smedt, S. C., Demeester, J., & Soenen, S. J. (2014) · Chemical Reviews · doi:10.1021/cr400372p · Cited by 244
Kato, K., Chin, K., Yoshikawa, T., Yamaguchi, K., Tsuji, Y., Esaki, T., Sakai, K., Kimura, M., Hamaguchi, T., Shimada, Y., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9709-2 · Cited by 237
“A previous phase I trial determined the recommended NK105 dose as 150 mg PTX equivalent/m(2) administered every 3 weeks [23].”
BackgroundMethodSelf-citationBiodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments
Karlsson, J., Vaughan, H. J., & Green, J. J. (2018) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-060817-084055 · Cited by 235
Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs
Gothwal, A., Khan, I., & Gupta, U. (2016) · Pharmaceutical Research · doi:10.1007/s11095-015-1784-1 · Cited by 233
Advances of Cancer Therapy by Nanotechnology
Wang, X., Wang, Y., Chen, Z. G., & Shin, D. M. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.1.1 · Cited by 230
Yokoyama, M. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903436479 · Cited by 224
“Matsumura and co-workers reported that NK-105 incorporating paclitaxel showed highly tumorselective delivery in murine tumor models [14,15,18,40,41].”
BackgroundOsada, K., Christie, R. J., & Kataoka, K. (2009) · Journal of The Royal Society Interface · doi:10.1098/rsif.2008.0547.focus · Cited by 218
Polymeric Micelles for Anticancer Drug Delivery
Majumder, N., G Das, N., & Das, S. K. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0008 · Cited by 217
Lv, S., Li, M., Tang, Z., Song, W., Sun, H., Liu, H., & Chen, X. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.08.015 · Cited by 213
“Accordingly, several polymeric nanoparticles of PEG-PAA incorporating doxorubicin, paclitaxel, SN-38 and cisplatin exhibited significant antitumor efficacy with appreciably lowered toxicity compared with free drugs, and are currently under clinical evaluation [23–26].”
BackgroundPolymeric micelles as drug carriers: their lights and shadows
Yokoyama, M. (2014) · Journal of Drug Targeting · doi:10.3109/1061186x.2014.934688 · Cited by 205
“For poly(ethylene glycol)-b-poly(amino acid) block copolymer-based polymeric micelle anti-cancer drugs, carrier-derived toxic side effects were not observed both in animal experiments or in clinical evaluations, while typical toxicities of anti-cancer drugs loaded in the polymeric micelles were observed to appear [47,…”
BackgroundWakaskar, R. R. (2018) · Journal of Drug Targeting · doi:10.1080/1061186x.2017.1367006 · Cited by 201
He, Z., Wan, X., Schulz, A., Bludau, H., Dobrovolskaia, M. A., Stern, S. T., Montgomery, S. A., Yuan, H., Li, Z., Alakhova, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.002 · Cited by 197
“Although it is not straightforward to compare MTD in mice or other animals to that in human, the relative MTDs of Taxol, Genexol-PM, Abraxane and NK105 correlated reasonably well with human MTD or recommended doses for these formulations [19–21].”
ResultPaclitaxel drug delivery systems
Zhang, Z., Mei, L., & Feng, S.-S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.752354 · Cited by 182
“NK105 is a new PTX-incorporating ‘core-shell-type’ polymeric micellar NP drug delivery system [40].”
BackgroundDevelopment of polymeric micelles for targeting intractable cancers
Nishiyama, N., Matsumura, Y., & Kataoka, K. (2016) · Cancer Science · doi:10.1111/cas.12960 · Cited by 180
Self-citationConcept and Clinical Evaluation of Carrier-Mediated Anticancer Agents
Zamboni, W. C. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0180 · Cited by 173
Clinical application of polymeric micelles for the treatment of cancer
Varela-Moreira, A., Shi, Y., Fens, M. H. A. M., Lammers, T., Hennink, W. E., & Schiffelers, R. M. (2017) · Materials Chemistry Frontiers · doi:10.1039/c6qm00289g · Cited by 168
The Rise and Rise of Stealth Nanocarriers for Cancer Therapy: Passive Versus Active Targeting
Huynh, N. T., Roger, E., Lautram, N., Benoît, J.-P., & Passirani, C. (2010) · Nanomedicine · doi:10.2217/nnm.10.113 · Cited by 164
Amphiphilic poly(l-amino acids) — New materials for drug delivery
Lalatsa, A., Schätzlein, A. G., Mazza, M., Le, T. B. H., & Uchegbu, I. F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.04.046 · Cited by 163
Lipids and polymers in pharmaceutical technology: Lifelong companions
Siepmann, J., Faham, A., Clas, S., Boyd, B. J., Jannin, V., Bernkop‐Schnürch, A., Zhao, H., Lecommandoux, S., Evans, J. C., Allen, C. J., et al. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.12.080 · Cited by 163
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 160
Application of Magnetic Nanoparticles to Gene Delivery
Kami, D., Takeda, S., Itakura, Y., Gojo, S., Watanabe, M., & Toyoda, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12063705 · Cited by 144
“Purpose References MRI Diagnosis [1–8,57–61] DDS Anti-cancer therapy, Enzyme therapy [9–11,22–31] Hyperthermia Anti-cancer therapy [12–18,33–37] Gene Delivery Anti-cancer therapy, Cell transplantation therapy [38–55]”
Nanoparticles containing insoluble drug for cancer therapy
Guo, S., & Huang, L. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.10.002 · Cited by 159
“Results from Phase I clinical studies showed that NK105 was well tolerated (Hamaguchi et al., 2007).”
BackgroundCabral, H., Makino, J., Matsumoto, Y., Mi, P., Wu, H., Nomoto, T., Toh, K., Yamada, N., Higuchi, Y., Konishi, S., et al. (2015) · ACS Nano · doi:10.1021/nn5070259 · Cited by 159
Cyclodextrin-derived pH-responsive nanoparticles for delivery of paclitaxel
He, H., Chen, S., Zhou, J., Dou, Y., Song, L., Che, L., Zhou, X. W., Chen, X., Jia, Y., Zhang, J., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.03.068 · Cited by 155
The in vivo fate of polymeric micelles
Cai, Y., Qi, J., Lu, Y., He, H., & Wu, W. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114463 · Cited by 154
Yokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 152
Bioinspired nanoarchitectonics as emerging drug delivery systems
Ariga, K., Kawakami, K., Ebara, M., Kotsuchibashi, Y., Ji, Q., & Hill, J. P. (2014) · New Journal of Chemistry · doi:10.1039/c4nj00864b · Cited by 136
Polymeric Micellar Delivery Systems in Oncology
Matsumura, Y. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn116 · Cited by 121
Self-citationTargeted Albumin-Based Nanoparticles for Delivery of Amphipathic Drugs
Xu, R., Fisher, M. H., & Juliano, R. L. (2011) · Bioconjugate Chemistry · doi:10.1021/bc1002295 · Cited by 132
The Chemistry of Bioconjugation in Nanoparticles-Based Drug Delivery System
Werengowska-Ciećwierz, K., Wiśniewski, M., Terzyk, A. P., & Furmaniak, S. (2015) · Advances in Condensed Matter Physics · doi:10.1155/2015/198175 · Cited by 131
“[160] proposed the new form of PTX-NK105, namely, the drug inside micelle (Figure 7).”
BackgroundInfluentialClinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 130
Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy
Huda, S., Alam, A., & Sharma, P. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102018 · Cited by 127
Amphiphilic block co-polymers: Preparation and application in nanodrug and gene delivery
Xiong, X.-B., Binkhathlan, Z., Molavi, O., & Lavasanifar, A. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.03.006 · Cited by 124
Quercetin Loaded Nanoparticles in Targeting Cancer: Recent Development
Vinayak, M., & Maurya, A. K. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190705150214 · Cited by 112
Lipid prodrug nanocarriers in cancer therapy
Mura, S., Bui, D. T., Couvreur, P., & Nicolas, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.021 · Cited by 122
Duong, H. H. P., & Yung, L. L. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.06.017 · Cited by 116
“Many polymeric micelles have been evaluated in vitro, in vivo and clinical trials and they have been found to be a potential drug carrier system (Hamaguchi et al., 2007; Kim et al., 2007; Li et al., 2012; Matsumura, 2008a,b; Matsumura and Kataoka, 2009; Rafi et al., 2012).”
BackgroundAn overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 114
Translating materials design to the clinic
Hubbell, J. A., & Langer, R. (2013) · Nature Materials · doi:10.1038/nmat3788 · Cited by 112
Taha, M. S., Padmakumar, S., Singh, A., & Amiji, M. M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-020-00744-1 · Cited by 108
“Similarly, Abraxane fails to improve paclitaxel pharmacokinetics due to rapid dissociation of the paclitaxel-albumin complexes in circulation [92, 93].”
BackgroundErnsting, M. J., Tang, W.-L., MacCallum, N., & Li, S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200284b · Cited by 105
Ernsting, M. J., Murakami, M., Undzys, E., Aman, A. M., Press, B., & Li, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.043 · Cited by 104
He, Z., Schulz, A., Wan, X., Seitz, J., Bludau, H., Alakhova, D. Y., Darr, D. B., Perou, C. M., Jordan, R., Ojima, I., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.024 · Cited by 99
“This formulation, designated as NK105, can incorporate 23% (w/w) PTX and has shown less toxicity and enhanced efficacy compared to free drug in the preclinical and clinical development [40,41].”
Micellar carriers for the delivery of multiple therapeutic agents
Thipparaboina, R., Chavan, R. B., Kumar, D. K., Modugula, S., & Shastri, N. R. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.046 · Cited by 97
Reddy, L. H., & Bazile, D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.007 · Cited by 97
Osorno, L. L., Brandley, A., Maldonado, D., Yiantsos, A., Mosley, R. J., & Byrne, M. E. (2021) · Nanomaterials · doi:10.3390/nano11020278 · Cited by 94
“PEG-pAsp Paclitaxel Advanced stomach cancer II [232]”
The use of Nanocarriers for Drug Delivery in Cancer Therapy David R. Khan
Khan, D. R. (2010) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000024 · Cited by 93
“NK105 and NC6004 are also both micellar-based drugs currently in either PhaseII or Phase-I/II stages of clinical trials (Hamaguchi et al., 2007; Wilson et al., 2008) (Table 1).”
BackgroundPolypeptide-based drug delivery systems for programmed release
Wang, X., Song, Z., Wei, S., Ji, G., Zheng, X., Fu, Z., & Cheng, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120913 · Cited by 92
Gong, C., Wei, X., Wang, X., Wang, Y., Guo, G., Mao, Y., Luo, F., & Qian, Z. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/21/215103 · Cited by 87
Overcoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic
Houdaihed, L., Evans, J. C., & Allen, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00188 · Cited by 91
Zhang, J., Ellsworth, K., & Ma, P. X. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.019 · Cited by 91
Current status of nanomedicine in the chemotherapy of breast cancer
Fraguas‐Sánchez, A. I., Martín‐Sabroso, C., Fernández-Carballido, A. M., & Torres‐Suárez, A. I. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03910-6 · Cited by 91
The Drug Discovery by NanoMedicine and its Clinical Experience
Matsumura, Y. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu046 · Cited by 80
Self-citationButt, A. M., Amin, M. C. I. M., Katas, H., Sarisuta, N., Witoonsaridsilp, W., & Benjakul, R. (2012) · Journal of Nanomaterials · doi:10.1155/2012/916573 · Cited by 82
“Some successful micellar nanocarriers have been studied in different phases of clinical trials [16–19].”
BackgroundWhat nanomedicine in the clinic right now really forms nanoparticles?
Svenson, S. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1257 · Cited by 85
Clinical developments of antitumor polymer therapeutics
Parveen, S., Arjmand, F., & Tabassum, S. (2019) · RSC Advances · doi:10.1039/c9ra04358f · Cited by 84
Polyamide/Poly(Amino Acid) Polymers for Drug Delivery
Boddu, S. H. S., Bhagav, P., Karla, P. K., Jacob, S., Adatiya, M. D., Dhameliya, T. M., Ranch, K. M., & Tiwari, A. K. (2021) · Journal of Functional Biomaterials · doi:10.3390/jfb12040058 · Cited by 83
“In addition, the recommended dose for phase II clinical trials and the pharmacokinetic profile of NK105 were also investigated [99].”
BackgroundDisposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery
Aliabadi, H. M., Shahin, M., Brocks, D. R., & Lavasanifar, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847100-00001 · Cited by 83
Nanocarriers in cancer clinical practice: a pharmacokinetic issue
Giodini, L., Re, F. L., Campagnol, D., Marangon, E., Posocco, B., Dreussi, E., & Toffoli, G. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.07.012 · Cited by 82
Polypeptides and polyaminoacids in drug delivery
González-Aramúndiz, J. V., Lozano, M. V., Sousa‐Herves, A., Fernández-Megía, E., & Csaba, N. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.647906 · Cited by 81
“The resulting micellar system, known as NK105, is under Phase II clinical studies in Japan (Table 1) [42].”
MethodBukhari, S. N. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14040866 · Cited by 80
Inoue, T., Yamashita, Y., Nishihara, M., Sugiyama, S., Sonoda, Y., Kumabe, T., Yokoyama, M., & Tominaga, T. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-068 · Cited by 79
Wei, X., Gong, C., Shi, S., Fu, S., Men, K., Zeng, S., Zheng, X., Gou, M., Chen, L., Qiu, L., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.10.027 · Cited by 77
Adityan, S., Tran, M. A., Bhavsar, C., & Wu, S. Y. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.016 · Cited by 76
Novel SN-38–Incorporated Polymeric Micelle, NK012, Strongly Suppresses Renal Cancer Progression
Sumitomo, M., Koizumi, F., Asano, T., Horiguchi, A., Ito, K., Asano, T., Kakizoe, T., Hayakawa, M., & Matsumura, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6532 · Cited by 72
Self-citationSakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
Self-citationResearch trends on nanomaterials in gastric cancer: a bibliometric analysis from 2004 to 2023
Ling, L., Ouyang, Y., & Hu, Y. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02033-8 · Cited by 75
Multifunctional approaches utilizing polymeric micelles to circumvent multidrug resistant tumors
Kesharwani, S. S., Kaur, S., Tummala, H., & Sangamwar, A. T. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.10.022 · Cited by 74
Rafi, M., Cabral, H., Kano, M. R., Mi, P., Iwata, C., Yashiro, M., Hirakawa, K., Miyazono, K., Nishiyama, N., & Kataoka, K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.038 · Cited by 73
Highly stable, ligand-clustered “patchy” micelle nanocarriers for systemic tumor targeting
Poon, Z., Lee, J. A., Huang, S., Prevost, R. J., & Hammond, P. T. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2010.07.008 · Cited by 66
“While clinical trials of micellar delivery systems have demonstrated improved pharmacokinetics and a greater tolerance with patients, dose-limiting toxicities attributed to the drug still occurs at higher dosage levels(9-11), suggesting that on some level, the encapsulated drug dissociates from the carrier in vivo.”
Polymers for targeted and/or sustained drug delivery
Jagur‐Grodzinski, J. (2008) · Polymers for Advanced Technologies · doi:10.1002/pat.1304 · Cited by 68
Seo, Y., Schulz, A., Han, Y., He, Z., Bludau, H., Wan, X., Tong, J., Bronich, T. K., Sokolsky, M., Luxenhofer, R., et al. (2015) · Polymers for Advanced Technologies · doi:10.1002/pat.3556 · Cited by 67
Clinical Translation of Self‐Assembled Cancer Nanomedicines
Mi, P., Miyata, K., Kataoka, K., & Cabral, H. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000159 · Cited by 65
Metadata
- Authors
- Hamaguchi, T., Kato, K., Yasui, H., Morizane, C., Ikeda, M., Ueno, H., Muro, K., Yamada, Y., Okusaka, T., Shirao, K., Shimada, Y., Nakahama, H., & Matsumura, Y.
- Affiliations
- National Cancer Center Hospital (JP)
- National Cancer Center Hospital East (JP)
- Corresponding author
- Hamaguchi, T
- ORCID
- Venue
- British Journal of Cancer
- Published
- 2007-06-26
- Volume
- 97
- Issue
- 2
- Pages
- 170-176
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2360299
- OpenAlex
- W1990869510
- Cited by
- 290
- References
- 24
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 10 · 2023: 5 · 2022: 13 · 2021: 10 · 2020: 16 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 18 · 2015: 23 · 2014: 29 · 2013: 29 · 2012: 22
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Keywords
- paclitaxel, polymeric micelles, maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, neutropenia, hypersensitivity, pancreatic cancer, cholangiocarcinoma, gastric cancer, colon cancer, accelerated titration
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Phytogenic, Digestive System Neoplasms, Female, Humans, Male, Micelles, Middle Aged, Tomography, X-Ray Computed, Paclitaxel, Maximum Tolerated Dose, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.